Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 471

Sort by

Sort Order Select

Journal Articles

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias

Blood (2019) 134 (Supplement_1): 618.

https://doi.org/10.1182/blood-2019-122062

Published: 2019

Journal Articles

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Farrukh Shah, MDMBBS,FRCPath, Paul Telfer, DM, FRCP, Mark Velangi, Shivan Pancham, Robert Wynn, Sally Pollard, Elizabeth Chalmers, Jonathan Kell, MD, Joe Hickey, PhD, Clark Paramore, MPH, Minesh Jobanputra, MD, Kate Ryan, MD

Blood (2019) 134 (Supplement_1): 3550.

https://doi.org/10.1182/blood-2019-129930

Published: 2019

Journal Articles

Neutropenia in Children Treated with Deferiprone or Deferasirox: A Report of the Largest Randomized Trial of Oral Chelators in Transfusion-Dependent Pediatric Patients

Fernando Tricta, MD, Mariagrazia Felisi, PhD, Oscar Della Pasqua, Amal El-Beshlawy, MD, Hoda Hassab, MD, Antonis Kattamis, Manika Kreka, MD, Giorgio Reggiardo, Laila Metwally Sherief, MD, Michael Spino, PharmD, Bianca Tempesta, PhD, Yu-Chung Tsang, PhD, Adriana Ceci, MD

Blood (2019) 134 (Supplement_1): 3552.

https://doi.org/10.1182/blood-2019-127933

Published: 2019

Journal Articles

Regulation of Iron Homeostasis By PTG-300 Improves Disease Parameters in Mouse Models for Beta-Thalassemia and Hereditary Hemochromatosis

Roopa Taranath, PhD, Gregory Bourne, PhD, Li Zhao, MD PhD, Brian Frederick, MS, Chelsea King, BA, David Liu, PhD

Blood (2019) 134 (Supplement_1): 3540.

https://doi.org/10.1182/blood-2019-129309

Published: 2019

Journal Articles

Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials

Natalia Scaramellini, MD, Carola Arighi, MD, Alessia Marcon, MD, Dario Consonni, MD, Elena Cassinerio, MD, Giovanna Graziadei, MD, Maria Domenica Cappellini, MD, Irene Motta, MD

Blood (2019) 134 (Supplement_1): 3542.

https://doi.org/10.1182/blood-2019-130237

Published: 2019

Journal Articles

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring

Andrea Piolatto, MS, Carmen Gaglioti, MD, Filomena Longo, MD, Silvia De Francia, PhD, Sarah Allegra, PhD, Paola Berchialla, PhD, Antonio Piga

Blood (2019) 134 (Supplement_1): 3547.

https://doi.org/10.1182/blood-2019-122030

Published: 2019

Journal Articles

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Blood (2019) 134 (Supplement_1): 3010.

https://doi.org/10.1182/blood-2019-129902

Published: 2019

Journal Articles

Review of Therapeutic Erythrocytapheresis in Patients with Thalassemia Major

Erika Wall, MD, Lauren Bolster, MD

Blood (2019) 134 (Supplement_1): 1176.

https://doi.org/10.1182/blood-2019-126809

Published: 2019

Journal Articles

Feasibility of Electronic Monitoring of Daily Oral Medications in Adolescents with Sickle Cell Disease

Lori E Crosby, PsyD, Katherine M Kidwell, PhD, Aimee K Hildenbrand, PhD, Charles T. Quinn, MD, Meghan E Mcgrady, PhD

Blood (2019) 134 (Supplement_1): 4701.

https://doi.org/10.1182/blood-2019-125875

Published: 2019

Journal Articles

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

Blood (2019) 134 (Supplement_1): 839.

https://doi.org/10.1182/blood-2019-127488

Published: 2019

Journal Articles

Trends in Iron Overload over Past Two Decades: Results from the Natural History of Iron Burden Study with the SQUID Biosusceptometer

Ashutosh Lal, MD, Roland Fischer, PhD, Elliott Vichinsky, MD UCSF, Marcela Weyhmiller, PhD

Blood (2019) 134 (Supplement_1): 961.

https://doi.org/10.1182/blood-2019-129701

Published: 2019

Journal Articles

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

James K. Mangan, MD PhD, Imran Ajmal, MBBS, Noelle V. Frey, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, Martin Carroll, MD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 5155.

https://doi.org/10.1182/blood-2019-131668

Published: 2019

Journal Articles

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Emanuele Angelucci, MD, Mario Capasso, PhD, Matteo Giovanni Della Porta, MD, Gian Luca Forni, Domenico Girelli, MD, PhD, Esther Natalie Oliva, MD, Federica Pilo, MD, Marino Clavio, MD, Marta Riva, MD, Annamaria Pelizzari, MD, Pasquale Niscola, MD PhD, Daniela Cilloni, MD PhD, Gianni Binotto, MD, Elena Crisà, MD, Valeria Santini, MD

Blood (2019) 134 (Supplement_1): 4256.

https://doi.org/10.1182/blood-2019-125575

Published: 2019

Journal Articles

Impact of Iron Overload and Iron Removal Therapy on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in the Patients with Severe Aplastic Anemia

Tianzhong Pan, Baolin Tang, Xiaoyu Zhu, Huilan Liu, Kaidi Song, Xiang Wan, Wen Yao, Zimin Sun

Blood (2019) 134 (Supplement_1): 5741.

https://doi.org/10.1182/blood-2019-130189

Published: 2019

Journal Articles

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

John Porter, Maria Domenica Cappellini, MD, Thomas Coates, MD, Olivier Hermine, Vip Viprakasit, MD DPhil, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Daniel Sinsimer, Ali Taher

Blood (2019) 134 (Supplement_1): 2245.

https://doi.org/10.1182/blood-2019-122561

Published: 2019

Journal Articles

A Unique Monocyte Transcriptome Discriminates Sickle Cell Disease from Other Hereditary Hemolytic Anemias and Shows the Particular Importance of Lipid and Interferon Signaling

Annelies J. Van Vuren, MD, Stephanie van Straaten, MD PhD, Michal Mokry, PhD, Richard van Wijk, PhD, Eduard J. van Beers, MD PhD

Blood (2019) 134 (Supplement_1): 980.

https://doi.org/10.1182/blood-2019-124070

Published: 2019

Journal Articles

Neurological Manifestations Due to Extramedullary Hematopoiesis in Greek Patients with Thalassemia Intermedia: Not Such a Rare Clinical Finding

Michael D. Diamantidis, MD PhD MSc, Alexandra Kourakli, MD PhD, Efthymia Vlachaki, MBBS, Despoina Pantelidou, MD PhD, Evgenia Verigou, Evangelos Alexiou, Fotios Girtovitis, PhD MD, Paraskevi Fotiou, Elisavet Grouzi, Argiris Symeonidis, MD PhD

Blood (2018) 132 (Supplement 1): 2349.

https://doi.org/10.1182/blood-2018-99-119376

Published: 2018

Journal Articles

Transfusion-Induced Impairment of Macrophage Responses Is Partially Restored By the Iron Chelator Deferasirox

Francesca Vinchi, PhD, Richard Sparla, Sara Passos, PhD, Heike Weidner, Martina Rauner, PhD, Uwe Platzbecker, Martina U. Muckenthaler, PhD

Blood (2018) 132 (Supplement 1): 3625.

https://doi.org/10.1182/blood-2018-99-113016

Published: 2018

Journal Articles

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Blood (2018) 132 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2018-99-118070

Published: 2018

Journal Articles

A Randomized Prospective Study to Assess the Effect of Vitamin E on Peroxiredoxin- 2 As a Novel Antioxidant Marker in Young Beta-Thalassemia Major Patients on Different Chelation Therapy

Mohamed Abd el mohsen, Maha Saber, Amira Adly, Eman Ismail, Omar Elalfy, MD, Elghamry Islam, Fatma Ibrahim, Mohsen Saleh Elalfy, MD

Blood (2018) 132 (Supplement 1): 1058.

https://doi.org/10.1182/blood-2018-99-115186

Published: 2018

NARROW

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias

Routine Management, Healthcare Resource Use and Patient/Caregiver-Reported Outcomes of Patients with Transfusion-Dependent β-Thalassaemia in the United Kingdom: A Mixed Methods Observational Study

Neutropenia in Children Treated with Deferiprone or Deferasirox: A Report of the Largest Randomized Trial of Oral Chelators in Transfusion-Dependent Pediatric Patients

Regulation of Iron Homeostasis By PTG-300 Improves Disease Parameters in Mouse Models for Beta-Thalassemia and Hereditary Hemochromatosis

Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Comparison of Deferasirox Formulations for Treatment Tailoring

Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement

Review of Therapeutic Erythrocytapheresis in Patients with Thalassemia Major

Feasibility of Electronic Monitoring of Daily Oral Medications in Adolescents with Sickle Cell Disease

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

Trends in Iron Overload over Past Two Decades: Results from the Natural History of Iron Burden Study with the SQUID Biosusceptometer

A Pilot Study of Exjade (Deferasirox) As Monotherapy in Higher Risk MDS or Acute Myeloid Leukemia

A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story

Impact of Iron Overload and Iron Removal Therapy on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in the Patients with Severe Aplastic Anemia

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

A Unique Monocyte Transcriptome Discriminates Sickle Cell Disease from Other Hereditary Hemolytic Anemias and Shows the Particular Importance of Lipid and Interferon Signaling

Neurological Manifestations Due to Extramedullary Hematopoiesis in Greek Patients with Thalassemia Intermedia: Not Such a Rare Clinical Finding

Transfusion-Induced Impairment of Macrophage Responses Is Partially Restored By the Iron Chelator Deferasirox

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

A Randomized Prospective Study to Assess the Effect of Vitamin E on Peroxiredoxin- 2 As a Novel Antioxidant Marker in Young Beta-Thalassemia Major Patients on Different Chelation Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only